Sartorius Names Incoming CEO as Chairman: Dr. Joachim Kreuzburg to Lead Company

Sartorius has named Dr. Joachim Kreuzburg as its incoming CEO and Chairman. Kreuzburg is a Co-Managing Director at Sartorius Ventures GmbH and has previously held various positions within the company. Sartorius is a Germany-based supplier of pharmaceutical and laboratory equipment, operating in two segments: bioprocess solutions and lab products and services. The company has 13,573 employees and is listed in the Advanced Medical Equipment & Technology sector.

Sartorius Stedim Biotech S.A. (SSB) has announced significant leadership changes following the resignation of Dr. Joachim Kreuzburg as the Board’s Chairman. In his place, Dr. Michael Grosse, who is set to succeed Kreuzburg as CEO of Sartorius AG, SSB’s majority shareholder, has been appointed as the new Chairman of the Board of SSB. This appointment comes as part of a strategic realignment within the company.

Michael Grosse, who holds a doctorate in mechanical engineering, brings extensive experience in the packaging industry for pharmaceuticals and food sectors. Prior to his appointment, Grosse served as the Chairman of the Management Board and Chief Executive Officer of Syntegon Technology GmbH from 2020 to 2023. He previously held executive roles at Tetra Pak and BMW, where he gained significant experience in product development and global service expansion.

The appointment of Grosse underscores Sartorius Stedim Biotech’s commitment to innovation and sustainability. The company has recently expanded its manufacturing and R&D capacities at its Aubagne campus, investing in cleanroom space, automation, and sustainability measures [3]. These investments align with the company’s goal to provide customers with innovative bioprocess solutions and enhance its competitive positioning.

Sartorius Stedim Biotech is a leading global partner in the biopharmaceutical industry, offering innovative solutions for the safe, rapid, and sustainable manufacture of biotech medications. With a strong global presence and a portfolio enriched through acquisitions, the company generated sales revenue of around 2.8 billion euros in 2024 [2].

The appointment of Michael Grosse as Chairman and CEO signals a new era for Sartorius Stedim Biotech, positioning the company for continued growth and innovation in the biopharmaceutical sector.

References:
[1] https://www.sartorius.com/en/company/newsroom/corporate-news/incoming-sartorius-ceo-michael-grosse-to-become-chairman-of-board-of-sartorius-stedim-biotech-sa-1699124
[2] https://www.tradingview.com/news/eqs:89a66148c094b:0-sartorius-stedim-biotech-sa-incoming-sartorius-ceo-michael-grosse-to-become-chairman-of-the-board-of-sartorius-stedim-biotech-s-a/
[3] https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-expands-manufacturing-and-r-d-capacities-for-innovative-bioprocess-solutions-in-france-1698362